Neurocrine Biosciences, Inc.

458 articles with Neurocrine Biosciences, Inc.

• Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - Nov 19, 2020

  11/19/2020

  Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences:.

• Neurocrine Biosciences Announces Repurchase of Convertible Notes

  11/19/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $83 million aggregate principal amount of the 2024 Notes

• Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - Nov 09, 2020

  11/9/2020

  Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences

• Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

  11/9/2020

   Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance.

• Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

  10/8/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Xenon Pharmaceuticals Inc. (Nasdaq: XENE) today provided an update on the ongoing collaboration for the clinical development of NBI-921352, previously known as XEN901

• Neurocrine Biosciences and Me2/Orchestra, in Partnership with Mental Health Advocacy Groups, Honor Mental Illness Awareness Week

  10/7/2020

  - Monumental Moments Encourages People to Share How They are Caring for Their Mental Health during These Unprecedented and Challenging Times on Social Media with Hashtag #MonumentalMoments - Me2/Orchestra, World's Only Known Classical Music Organization Created for Individuals with Mental Illness, to Unveil Original Musical Score Inspired by the Personal Experiences of its 100+ Members - Neurocrine Biosciences Will Donate to Mental Health Organizations as Part of Initiative t

• Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

  10/6/2020

   Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 9, 2020 . Neurocrine will then host a conference call and webcast to discuss its finan

• Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting

  9/28/2020

  - ONGENTYS, the First and Only Once-Daily COMT Inhibitor, Led to Greater Reductions in Overnight "Off" Time and Time to Morning "On" Time Compared to Entacapone When Used as an Add-On Therapy in Patients with Parkinson's Disease with Motor Fluctuations in a Post-Hoc, Sub-Group Analysis of the Phase III, BIPARK-1 Study - New Phase III Post-Hoc Sub-Group Analysis Demonstrates that Long-Term Treatment with ONGENTYS When Used as an Add-On Therapy Reduced "On&qu

• Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

  9/14/2020

  - ONGENTYS, the First and Only FDA-Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa - FDA Approval of ONGENTYS Supported by Data from 38 Clinical Studies, Including Two Multinational Phase III Clinical Studies (BIPARK-1 and BIPARK-2), with More Than 1,000 Parkinson's Disease Patients Treated with ONGENTYS   [14-S

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

  9/11/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS® (opicapone) capsules decreased "off" time and increased "on" time without troublesome dyskinesia as an add-on therapy to levodopa/carbidopa in patients with Parkinson's disease who experience motor fluctuations.

• Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson's Disease

  9/11/2020

  NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater "On" Time without Troublesome Dyskinesia and Reduction in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Scores, and Reduction in the Amount of Medications Up to Three Years in Patients with Parkinson's Disease

• 

  An Overview of Citi’s 15th Annual BioPharma Conference 2020 Boston

  9/9/2020

  Like almost all conferences this year, Citi’s 15th Annual BioPharma Conference 2020 is being held virtually.

• Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

  9/8/2020

   Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020.

• Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings

  9/3/2020

  -- New Three-Year Gene Therapy Data for Parkinson's Disease Part of 30 Abstracts to be Presented at 2020 Psych Congress and the MDS Virtual Congress 2020 -- - INGREZZA® (valbenazine) Data Analyses from Long-Term Phase III Studies Demonstrate Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia - New Phase III Data Analyses of ONGENTYS® (opicapone) Support Treatment as Add-On Therapy to Levodopa/Carbidopa for Parkinson's Patients with Motor F

• Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference

  9/2/2020

  Neurocrine Biosciences, Inc. will present at the Citi 15th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday, September 9, 2020.

• Neurocrine Biosciences Reports Second Quarter 2020 Financial Results

  8/3/2020

  INGREZZA® (valbenazine) Second Quarter Net Product Sales of $268 million with Approximately 46,400 TRx

• Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020

  7/30/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020.

• Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2020 Financial Results

  7/13/2020

  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020

• Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

  6/16/2020

  Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio